AlloStim

BIOLOGICAL11 trials

Sponsors

Mirror Biologics, Inc., Michael Har-Noy

Conditions

ARDS, HumanAdvanced Adult Hepatocellular CarcinomaBreast CancerCOVID-19 Respiratory InfectionCancer of Head and NeckColorectal CancerColorectal Cancer MetastaticHematological Malignancy

Phase 1

A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy

CompletedNCT00558675

Mirror Biologics, Inc.Hematological Malignancy, Leukemia, Lymphoma +1

Start: 2010-12-31End: 2013-03-31Updated: 2020-01-22

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

CompletedNCT01065441

Michael Har-NoyBreast Cancer, Colorectal Cancer, Melanoma +5

Start: 2010-12-31End: 2013-07-31Updated: 2020-01-22

In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer

WithdrawnNCT01923233

Mirror Biologics, Inc.Hepatocellular Carcinoma

Start: 2014-11-30End: 2015-06-30Updated: 2020-01-22

An Individualized Anti-Cancer Vaccine Study in Patients With HCC

WithdrawnNCT01995227

Mirror Biologics, Inc.Hepatocellular Carcinoma

Start: 2013-12-31End: 2018-07-31Updated: 2020-01-22

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

WithdrawnNCT02018419

Mirror Biologics, Inc.Metastatic Breast Cancer

Start: 2014-03-31End: 2014-03-31Updated: 2020-01-22

Universal Anti-Viral Vaccine for Healthy Elderly Adults

CompletedNCT04441047

Mirror Biologics, Inc.ARDS, Human, COVID-19 Respiratory Infection, Influenza, Human +3

Start: 2021-07-12End: 2024-11-01Updated: 2025-01-14

Phase 2

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck

CompletedNCT01998542

Mirror Biologics, Inc.Cancer of Head and Neck, Squamous Cell Carcinoma of the Head and Neck

Start: 2016-01-31End: 2017-11-30Updated: 2020-01-23

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

CompletedNCT02380443

Mirror Biologics, Inc.Colorectal Cancer Metastatic

Start: 2016-09-30End: 2018-09-30Updated: 2025-05-16

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

CompletedNCT02409524

Mirror Biologics, Inc.Advanced Adult Hepatocellular Carcinoma

Start: 2016-07-31End: 2019-03-31Updated: 2020-01-22

Immunotherapy for Third Line Metastatic Colorectal Cancer

CompletedNCT04444622

Mirror Biologics, Inc.Metastatic Colorectal Cancer

Start: 2021-07-12End: 2025-03-31Updated: 2025-10-20

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

WithdrawnNCT06557278

Mirror Biologics, Inc.Metastatic Colorectal Cancer

Start: 2026-11-30End: 2028-11-30Updated: 2025-10-21

Related Papers

Allo-Priming Reverses Immunosenescence and May Restore Broad Respiratory Viral Protection and Vaccine Responsiveness to the Elderly: Results of a Phase I/II Clinical Trial

Vaccines2025-04-25

A phase 2, multicenter, open-label study of AlloStim combined with anti-PD-L1immunotherapy as 4L therapy in patients with MSS/pMMR metastatic colorectal cancer.

Journal of Clinical Oncology2025-01-27

A phase 2, multicenter, open-label study of AlloStim in-situ cancer vaccine immunotherapy as 3L therapy in MSS/pMMR metastatic colorectal cancer.

Journal of Clinical Oncology2025-01-27

Objective response after immune checkpoint inhibitors in a chemotherapy-refractory pMMR/MSS metastatic rectal cancer patient primed with experimental AlloStim® immunotherapy

Translational Medicine Communications2024-05-14

Effect of therapeutic vaccine on CTLA4 and tumor debulking response in recurrent and metastatic HNSCC.

Journal of Clinical Oncology2018-02-106 citations

Personalized vaccine for advanced HCC.

Journal of Clinical Oncology2018-02-01

Phase I/IIb trial: In-situ vaccine for metastatic colorectal cancer.

Journal of Clinical Oncology2018-02-01